CBLL
Ceribell, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$26.00
+3.83%Year over year
Reported trailing growth
- Revenue
- +31.7%
- EBITDA
- -36.5%
- EBIT
- -34.6%
- EPS
- -21.4%
- Free cash flow
- -45.5%
- Operating cash flow
- -44.3%
Forward estimates
Based on analyst estimates
- Revenue
- +36.3%
- EBITDA
- +3.3%
- EPS
- +4.5%
Three-year CAGR
- Revenue
- +50.9%
- EBITDA
- -34.5%
- EBIT
- -47.1%
- Net income
- -32.0%
- EPS
- -29.2%
- Free cash flow
- -14.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026